Dec 06, 2021
News
At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.
Nov 09, 2021
NGM Bio to Participate in Upcoming Investor Conferences
Nov 04, 2021
NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
Sep 16, 2021
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021
Aug 23, 2021
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research
Aug 05, 2021
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results
Jul 22, 2021
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Jul 07, 2021
NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors
Jul 01, 2021
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases
Jun 07, 2021
NGM Bio to Present at Two Upcoming Investor Conferences
May 24, 2021
NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
May 23, 2021
NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
May 06, 2021
NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results
Apr 28, 2021
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
Mar 04, 2021
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 02, 2021
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer
Feb 25, 2021
NGM Bio to Present at the Cowen 41st Annual Health Care Conference
Feb 09, 2021
NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
Jan 12, 2021
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
Jan 05, 2021
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
Jan 04, 2021